Table 2.
The BNCT Tumor Doses, OS, PFS, Treatment Failure Rate, and CTCAE Data of HGM Patients
| Tumor dose of BNCT, Gy-Eq: | |||
| Max | Mean, SD | 68.7 | 18.2 |
| Median, range | 72 | 22.7–111.5 | |
| Min | Mean, SD | 36.7 | 16.4 |
| Median, range | 33.7 | 9.5–71.4 | |
| OS from BNCT (44 cases), months: | |||
| WHO grade 2 + 3 | Median, range | 29.6 | 6.4–103 |
| WHO grade 2 | 44.4 | 6.4–103 | |
| WHO grade 3 | 21.55 | 7.5–60.4 | |
| OS from diagnosis (44 cases), months: | |||
| WHO grade 2 + 3 | Median, range | 98.4 | 25.6–344.8 |
| WHO grade 2 | 224.4 | 29.3–325.3 | |
| WHO grade 3 | 69.6 | 25.6–344.8 | |
| PFS (36 cases), months: | |||
| WHO grade 2 + 3 | Median, range | 13.7 | 1.4–90.5 |
| WHO grade 2 | 24.3 | 5.1–90.5 | |
| WHO grade 3 | 9.4 | 1.4–39.4 | |
| Treatment failure (36 cases), n, % | 36 | ||
| Local | 8 | 22.2% | |
| Out of field | 11 | 30.6% | |
| Systemic metastasis | 4 | 11.1% | |
| Dissemination | 3 | 8.3% | |
| Others | 2 | 5.6% | |
| CNS necrosis (44 cases), n, %: | |||
| CTCAE grade | |||
| Grade 2 | 15 | 34.1% | |
| Grade 3 | 6 | 13.6% |
Abbreviations: BNCT = boron neutron capture therapy; CNS = central nervous system; CTCAE = Common Terminology Criteria for Adverse Events; HGM = High-grade meningioma; OS = overall survival; PFS = progression-free survival; WHO = World Health Organization.